{"organizations": [], "uuid": "6fc7d6742436ff6f60555f53830cfbe3c0107939", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-gensight-biologics-reports-55-mill/brief-gensight-biologics-reports-55-million-euros-2017-year-end-cash-position-idUSFWN1PK0E1", "country": "US", "domain_rank": 408, "title": "BRIEF-Gensight Biologics Reports 55 Million Euros 2017 Year-End Cash Position", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.649, "site_type": "news", "published": "2018-01-25T17:20:00.000+02:00", "replies_count": 0, "uuid": "6fc7d6742436ff6f60555f53830cfbe3c0107939"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gensight-biologics-reports-55-mill/brief-gensight-biologics-reports-55-million-euros-2017-year-end-cash-position-idUSFWN1PK0E1", "ord_in_thread": 0, "title": "BRIEF-Gensight Biologics Reports 55 Million Euros 2017 Year-End Cash Position", "locations": [], "entities": {"persons": [{"name": "gensight", "sentiment": "negative"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - GENSIGHT BIOLOGICS SA:\n* GENSIGHT BIOLOGICS REPORTS â‚¬55 MILLION 2017 YEAR-END CASH POSITION AND PROVIDES CORPORATE UPDATE\n* TOPLINE RESULTS OF REVERSE AND RESCUE ARE EXPECTED IN APRIL AND 3Q 2018, RESPECTIVELY.\n* REFLECT, PHASE III CLINICAL TRIAL: FIRST PATIENT IS EXPECTED TO BE TREATED IN 1Q 2018 IN US.\n* PIONEER PHASE I/II CLINICAL TRIAL: FIRST PATIENT IS EXPECTED TO BE TREATED IN 1Q 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T17:20:00.000+02:00", "crawled": "2018-01-26T21:22:03.001+02:00", "highlightTitle": ""}